The development of highly active regimens for patients with hematologic malignancies has yielded significant benefits in terms of response and survival. Nevertheless, even after achieving a clinical response, a portion of patients will experience relapse due to the presence of measurable (or minimal) residual disease (MRD) after therapy. An important focus of clinical research in hematologic malignancies consists of determining what additional treatment is appropriate for a patient who is MRD-positive. The incorporation of MRD status in the treatment algorithm also triggers other important decisions, such as selecting an assay, determining sensitivity levels, and assessing the impact of other factors, such as high-risk disease characteristics. It is important for clinicians to effectively evaluate and manage MRD in order to maximize the benefits of antineoplastic therapy.
The learning objectives of this program are:
· Outline the techniques and platforms available for MRD assessment across hematologic malignancies
· Identify guideline recommendations and expert consensus for the use of MRD monitoring in the management of hematologic malignancies
· Integrate MRD assessment into treatment planning for hematologic malignancies across the continuum of care
· Evaluate emerging data regarding sampling techniques and MRD assessment in clinical trial design for hematologic malignancies
This educational activity is directed toward medical oncologists, hematologists, and other oncology health care professionals interested in the latest advances in MRD monitoring for patients with hematologic malignancies. Fellows, researchers, nurses, nurse practitioners, physician assistants, and other health care professionals interested in MRD monitoring for patients with hematologic malignancies are also invited to participate.
December 10, 2021
Registration and Lunch: 2:15 PM – 3:00 PM EST
Scientific Session: 3:00 PM – 6:00 PM EST
Jerald P. Radich, MD
Professor, Medical Oncology Division
University of Washington School of Medicine
Clinical Research Division
Fred Hutchinson Cancer Research Center